Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC - Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $28.00 target price on the biotechnology company's stock. HC Wainwright also issued estimates for Benitec Biopharma's Q4 2025 earnings at ($0.25) EPS and FY2025 earnings at ($1.33) EPS.

Separately, JMP Securities reaffirmed a "market outperform" rating and issued a $20.00 target price on shares of Benitec Biopharma in a research note on Thursday, May 15th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $24.71.

Benitec Biopharma Trading Down 2.9%

Shares of Benitec Biopharma stock traded down $0.40 on Monday, reaching $13.19. The stock had a trading volume of 36,388 shares, compared to its average volume of 41,153. Benitec Biopharma has a 1 year low of $5.74 and a 1 year high of $16.90. The company has a market cap of $337.66 million, a P/E ratio of -8.74 and a beta of 0.34. The business's 50 day moving average is $13.54 and its two-hundred day moving average is $12.12.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12. On average, equities analysts anticipate that Benitec Biopharma will post -1.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L bought 900,000 shares of the stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $13.00 per share, for a total transaction of $11,700,000.00. Following the purchase, the director now owns 8,793,245 shares of the company's stock, valued at approximately $114,312,185. The trade was a 11.40% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Benitec Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. grew its holdings in Benitec Biopharma by 138.4% during the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after buying an additional 20,597 shares in the last quarter. 683 Capital Management LLC purchased a new stake in Benitec Biopharma during the 4th quarter valued at approximately $452,000. Northern Trust Corp grew its holdings in Benitec Biopharma by 54.2% during the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after buying an additional 13,425 shares in the last quarter. Informed Momentum Co LLC purchased a new stake in Benitec Biopharma during the 1st quarter valued at approximately $512,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Benitec Biopharma during the 1st quarter valued at approximately $597,000. Hedge funds and other institutional investors own 52.19% of the company's stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.